Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PET… Read more
Sprint Bioscience AB (SPRINT) - Net Assets
Latest net assets as of September 2025: Skr6.06 Million SEK
Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has net assets worth Skr6.06 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr21.44 Million) and total liabilities (Skr15.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr6.06 Million |
| % of Total Assets | 28.29% |
| Annual Growth Rate | 12.4% |
| 5-Year Change | 1.4% |
| 10-Year Change | 92.36% |
| Growth Volatility | 251.36 |
Sprint Bioscience AB - Net Assets Trend (2011–2024)
This chart illustrates how Sprint Bioscience AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sprint Bioscience AB (2011–2024)
The table below shows the annual net assets of Sprint Bioscience AB from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr9.27 Million | -66.62% |
| 2023-12-31 | Skr27.77 Million | -1.47% |
| 2022-12-31 | Skr28.19 Million | -59.99% |
| 2021-12-31 | Skr70.45 Million | +670.49% |
| 2020-12-31 | Skr9.14 Million | -17.00% |
| 2019-12-31 | Skr11.02 Million | -70.42% |
| 2018-12-31 | Skr37.24 Million | +32.59% |
| 2017-12-31 | Skr28.09 Million | -1.42% |
| 2016-12-31 | Skr28.49 Million | +491.15% |
| 2015-12-31 | Skr4.82 Million | -76.28% |
| 2014-12-31 | Skr20.32 Million | +504.23% |
| 2013-12-31 | Skr3.36 Million | +206.55% |
| 2012-12-31 | Skr1.10 Million | -45.92% |
| 2011-12-31 | Skr2.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sprint Bioscience AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27030155000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr6.98 Million | 75.30% |
| Other Components | Skr273.67 Million | 2951.59% |
| Total Equity | Skr9.27 Million | 100.00% |
Sprint Bioscience AB Competitors by Market Cap
The table below lists competitors of Sprint Bioscience AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Global Consumer Public Company Limited
BK:GLOCON
|
$13.41 Million |
|
Youil Energy Technology Co. Ltd.
KQ:340930
|
$13.41 Million |
|
Eureka Homestead Bancorp Inc
PINK:ERKH
|
$13.41 Million |
|
EVZ Ltd
AU:EVZ
|
$13.41 Million |
|
Brainzcompany Co. Ltd.
KQ:099390
|
$13.39 Million |
|
Iep Invest
BR:IEP
|
$13.39 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
$13.39 Million |
|
Lulu's Fashion Lounge Holdings Inc
NASDAQ:LVLU
|
$13.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sprint Bioscience AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 27,774,000 to 9,272,000, a change of -18,502,000 (-66.6%).
- Net loss of 18,277,000 reduced equity.
- Share repurchases of 225,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-18.28 Million | -197.12% |
| Share Repurchases | Skr225.00K | -2.43% |
| Total Change | Skr- | -66.62% |
Book Value vs Market Value Analysis
This analysis compares Sprint Bioscience AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 7.10x to 16.04x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | Skr0.30 | Skr2.13 | x |
| 2012-12-31 | Skr0.16 | Skr2.13 | x |
| 2013-12-31 | Skr0.50 | Skr2.13 | x |
| 2014-12-31 | Skr2.32 | Skr2.13 | x |
| 2015-12-31 | Skr0.55 | Skr2.13 | x |
| 2016-12-31 | Skr3.12 | Skr2.13 | x |
| 2017-12-31 | Skr2.86 | Skr2.13 | x |
| 2018-12-31 | Skr3.14 | Skr2.13 | x |
| 2019-12-31 | Skr0.73 | Skr2.13 | x |
| 2020-12-31 | Skr0.44 | Skr2.13 | x |
| 2021-12-31 | Skr2.03 | Skr2.13 | x |
| 2022-12-31 | Skr0.67 | Skr2.13 | x |
| 2023-12-31 | Skr0.40 | Skr2.13 | x |
| 2024-12-31 | Skr0.13 | Skr2.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sprint Bioscience AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -197.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27.84%
- • Asset Turnover: 1.56x
- • Equity Multiplier: 4.54x
- Recent ROE (-197.12%) is below the historical average (-152.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -67.88% | -58.15% | 0.85x | 1.37x | Skr-1.58 Million |
| 2012 | -323.17% | -223.21% | 0.37x | 3.92x | Skr-3.65 Million |
| 2013 | -130.45% | -185.03% | 0.32x | 2.22x | Skr-4.72 Million |
| 2014 | -56.41% | -248.67% | 0.18x | 1.24x | Skr-13.50 Million |
| 2015 | -321.56% | -200.61% | 0.25x | 6.36x | Skr-15.98 Million |
| 2016 | 15.94% | 12.98% | 0.71x | 1.74x | Skr1.69 Million |
| 2017 | -37.96% | -44.49% | 0.68x | 1.26x | Skr-13.47 Million |
| 2018 | -59.65% | -123.86% | 0.30x | 1.59x | Skr-25.94 Million |
| 2019 | -206.44% | -67.81% | 1.74x | 1.75x | Skr-23.85 Million |
| 2020 | -505.61% | -273.81% | 0.51x | 3.65x | Skr-47.15 Million |
| 2021 | -35.98% | -72.20% | 0.44x | 1.12x | Skr-32.40 Million |
| 2022 | -213.46% | -72493.98% | 0.00x | 1.33x | Skr-62.99 Million |
| 2023 | -1.58% | -0.87% | 0.81x | 2.25x | Skr-3.22 Million |
| 2024 | -197.12% | -27.84% | 1.56x | 4.54x | Skr-19.20 Million |
Industry Comparison
This section compares Sprint Bioscience AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sprint Bioscience AB (SPRINT) | Skr6.06 Million | -67.88% | 2.54x | $13.41 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |